RA Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

RA Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3M	Hold	5,000,000	–	–	0.2%	60
2026 Q1	$28.7M	Hold	5,000,000	–	–	0.3%	47
2025 Q4	$49.6M	Buy	+5,000,000	New	+$45.6M	0.51%	35
2025 Q2	–	Sell	-546,554	Closed	-$1.9M	–	79
2025 Q1	$1.9M	Hold	546,554	–	–	0.03%	83
2024 Q4	$3.6M	Hold	546,554	–	–	0.05%	85
2024 Q3	$4.94M	Sell	546,554 -126,158	-19%	-$1.5M	0.06%	73
2024 Q2	$10.8M	Buy	672,712 +11,774	+2%	+$171K	0.14%	66
2024 Q1	$10.4M	Buy	+660,938	New	+$10.3M	0.13%	70

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RA Capital Management's LXEO Position: Q2 2026 in Review

RA Capital Management held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 5,000,000 shares worth $23.3M. The position accounts for 0.2% of the portfolio, ranked #60.

RA Capital Management first reported a position in LXEO in Q1 2024 and has held it in 8 quarters since. The position peaked at $49.6M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

RA Capital Management held 5,000,000 shares of Lexeo Therapeutics worth $23.3M as of Q2 2026.
RA Capital Management left its Lexeo Therapeutics share count unchanged in Q2 2026.
Lexeo Therapeutics made up 0.2% of RA Capital Management's portfolio in Q2 2026, its #60 holding.
RA Capital Management first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 8 quarters since.
RA Capital Management's Lexeo Therapeutics position peaked at $49.6M in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.